

Expanded View Figures




Figure EV1. Detailed follow-up of healthy subjects receiving sitagliptin.

Based on short CXCL10 levels as a pharmacodynamic response to sitagliptin treatment, three categories of subjects were defined: responders ($n = 18$), in which short CXCL10 levels are steadily undetectable upon sitagliptin treatment; partial responders ($n = 6$), which shows a sporadic rise in short CXCL10 upon treatment; and nonresponders ($n = 3$), which shows no change in short CXCL10 levels. For the three groups, the percentage of DPP4 activity and the levels of short, long, and total CXCL10 are shown.




Figure EV2. Chronic HCV patients' viral loads.